Older patients' prescriptions screening in the community pharmacy: development of the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP3S) tool by Tommelein, Eline et al.
  
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for all 
UGent research publications. Ghent University has implemented a mandate stipulating that all 
academic publications of UGent researchers should be deposited and archived in this repository. 
Except for items where current copyright restrictions apply, these papers are available in Open 
Access. 
 
This item is the archived peer-reviewed author-version of: 
Title: Older Patients’ Prescriptions Screening in the Community Pharmacy: Development of the 
Ghent Older People's Prescriptions Community Pharmacy Screening (GheOP3S) Tool 
Authors: Tommelein, Eline, Mirko Petrovic, Annemie Somers, Els Mehuys, Tischa van der Cammen, 
and Koen Boussery 
In: Journal of Public Health 38 (2): e158–e170,  2016. 
 
To refer to or to cite this work, please use the citation to the published version: 
Tommelein, Eline, Mirko Petrovic, Annemie Somers, Els Mehuys, Tischa van der Cammen, and Koen 
Boussery. 2016. “Older Patients’ Prescriptions Screening in the Community Pharmacy: 
Development of the Ghent Older People's Prescriptions Community Pharmacy Screening (GheOP3S) 
Tool.” Journal of Public Health 38 (2): e158–e170. doi:10.1093/pubmed/fdv090 
 
 
 
 
 
 
 
Older patients’ prescriptions screening in the community pharmacy: development of the Ghent Older 
People’s Prescriptions community Pharmacy Screening (GheOP³S) tool 
Eline Tommelein
1
, Mirko Petrovic
2
, Annemie Somers
3
, Els Mehuys
1
, Tischa van der Cammen
4
, Koen Boussery
1 
1 Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Gent, Belgium 
2 Department of Internal medicine, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, B-9000 Gent, Belgium 
3 Department of Pharmacy, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium 
 4 Department of Internal Medicine, Section of Geriatric Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The 
Netherlands 
Corresponding Author & Requests for Single Reprints:  
Eline Tommelein 
Pharmaceutical Care Unit – Faculty of Pharmaceutical Sciences,  
Ottergemsesteenweg 460 
B-9000 Ghent (Belgium)  
Tel: +32 92648073 
Fax: +32 92648197 
E-mail: Eline.Tommelein@UGent.be  
 
 
Word count Abstract: 197 
Word count Manuscript: 2893
 ABSTRACT 
Background. Aging of the population often leads to polypharmacy. Consequently, Potentially Inappropriate 
Prescribing (PIP) becomes more frequent. Systematic screening for PIP in older patients in primary care could 
yield a large improvement in health outcomes, possibly an important task for community pharmacists. In this 
manuscript, we develop an explicit screening tool to detect relevant PIP that can be used in the typical 
community pharmacy practice, adapted to the European market.  
Methods.  Eleven panellists participated in a two-round RAND/UCLA (Research and Development/University of 
California, Los Angeles) process, including a round zero meeting, a literature review, a first written evaluation 
round, a second face-to-face evaluation round, and finally, a selection of those items that are applicable in the 
contemporary community pharmacy. 
Results. Eighteen published lists of PIP for older patients were retrieved from the literature, mentioning 398 
different items. After the two-round RAND/UCLA process, 99 clinically relevant items were considered suitable 
to screen for in a community pharmacy practice. A panel of seven community pharmacists selected 83 items, 
feasible in the contemporary community pharmacy practice, defining the final GheOP³S-tool.  
Conclusion. A novel explicit screening tool (GheOP³S) was developed to be used for PIP-screening in the typical 
community pharmacy practice.  
KEYWORDS: Screening, Primary care, Health services 
KEY POINTS 
- The GheOP³S-tool is the first explicit screening tool, specifically designed for use in the community 
pharmacy practice. 
- Identification of PIP in the community pharmacy practice is aimed at facilitating pharmacist discussion 
with patients and health care providers 
- Using the GheOP³S-tool, community pharmacists could play a supportive role in a prescription process 
in which the most beneficial and clinically effective medication with the lowest possible risk for 
adverse drug events is delivered to the older patient. 
 INTRODUCTION 
The population of older patients is increasing in most European countries(1). Because of co-morbidities and 
polypharmacy, in addition to age-related changes in pharmacokinetics and pharmacodynamics, older patients 
are more at risk for adverse drug events (ADEs), leading to increased morbidity, mortality and financial costs(2, 
3). ADE prevalence has been shown to be associated with Potentially Inappropriate Prescribing (PIP)(4). PIP 
comprises overuse, underuse and misuse of drugs(5) and is thus a potential, though indirect, cause for 
increased social and economic burden(1, 6). Despite increasing awareness of PIP in older patients and its 
consequences, PIP prevalence remains high(7, 8).  
Several interventions aiming to reduce PIP in older patients have been proposed and evaluated(9). Most of 
these interventions apply an approach that involves a (clinical) pharmacist who initiates a screening process 
using a specifically developed screening tool(9). However, most of these screening tools have been designed 
and validated solely in hospitals or nursing home settings(10-23), and often require clinical and laboratory 
information, usually unavailable to the community pharmacist. Therefore, studies that investigate PIP in 
primary care need to either modify or can only use portions of existing screening criteria(24-27). Furthermore, 
some screening tools lack scientific evidence, are not yet validated in clinical practice, do not offer alternative 
therapeutic options or are not adapted to the European market(10-12, 22). Yet, it seems reasonable that 
systematic screening for PIP in older patients in primary care could yield a large improvement in health 
outcomes(28).  
The community pharmacist may be ideally placed to engage in this process because of his medication-specific 
knowledge and because of the availability of an electronic dispensing record in the pharmacy. However, this 
engagement would require an evidence-based and feasible screening tool specifically suitable for use in the 
typical community pharmacy practice. Such a tool, to the best of our knowledge, has not yet been developed. 
In this manuscript, we therefore present the development of the GheOP³S-tool: the Ghent Older People’s 
Prescriptions community Pharmacy Screening tool.   
 METHODS  
Design summary 
The GheOP³S-tool was developed in five steps, based on the RAND/UCLA (Research and 
Development/University of California Los Angeles) method(29). It included (i) a round zero meeting, (ii) a 
literature review, (iii) a first written Delphi round, (iv) a second face-to-face Delphi round based on the first 
round evaluation, and (v) finally, a selection of those items considered applicable in the contemporary 
community pharmacy practice.  
Round zero meeting 
In the round zero meeting the research team (ET, MP, AS, EM, KB) reached consensus on the working 
procedures, and on a 5-part structure for the GheOP³S-tool: Part 1: Potentially inappropriate drugs, 
independent of diagnosis, Part 2: Potentially inappropriate drugs, dependent on diagnosis, Part 3: Potential 
Prescribing Omissions (PPOs), Part 4: Drug-Drug Interactions (DDIs) of specific relevance and Part 5: General 
care-related items to be addressed in the community pharmacy (Table 1). This structure was deliberately 
chosen to make community pharmacists familiar with the existence of different types of PIP (underuse, overuse 
and misuse). Furthermore, this structure offers the opportunity of a stepwise implementation of the tool.  
Literature review  
To identify previously developed screening tools for the detection of PIP in older adults, a literature search was 
performed within the PubMed database, using following terms and/or combinations: “elderly”, “older age”, 
“Aged”, “inappropriate prescribing”, “inappropriate medication”, “protocol”, ”criteria” and “screening tool”. All 
articles published between January 1990 and December 2012 were eligible if they contained explicit criteria 
addressing inappropriate prescribing in older patients. For lists that were updated (such as Beers List), only the 
most recent version was included. References of included articles were manually searched for completeness.  
A total of 18 explicit lists were retrieved (10-23, 30-33) and summarized. All mentioned items were classified 
into the 5-part-structure of the GheOP³S-tool. Criteria to withhold items for evaluation by the Delphi-panel 
were determined for each part of the tool (See Appendix 1). This way, a literature-based list of potential items 
for the tool was created. Furthermore, the literature review was extended with an up-to-date summary of the 
best available scientific evidence regarding all withheld items. Where evidence from randomized controlled 
trials was missing, the review also included lower quality of evidence. Additionally, for each PIP item, an 
alternative therapeutic option was offered, relying on existing evidence.   
First Delphi round: written individual evaluation 
The research team invited a 12-person multidisciplinary Delphi panel encompassing all decision-making 
disciplines involved in geriatric care, including 4 clinical pharmacists, 2 geriatricians, 2 general practitioners, 2 
academics, one community pharmacist, and an emergency physician. Eleven panellists from various European 
countries agreed to participate. The main selection criteria for panellists were acknowledged leadership in the 
panel member’s specialty, absence of conflicts of interest, geographic diversity and diversity of practice setting.  
In February 2013, all participating panellists were provided with the literature review and a scoring form. For 
each item, panellists were asked to reply to the following questions considering scientific evidence from the 
literature review and using their best clinical judgement: “How do you rate the added clinical value of a check 
on this item for an older patient by the community pharmacist?” and “How do you rate the proposed 
alternative?”. Prescribing and sales data of the proposed items were available to the panellists upon request. 
Practical aspects considering the organization of community pharmacies in the panellist’s country and cost 
implications were on the other hand specifically instructed to be excluded in making this judgement (e.g., 
access to patients’ clinical records at the community pharmacy had not be taken into account). All items were 
scored on a scale, ranging from 1 to 9, with 1 indicating that checking for this item in the community pharmacy 
has no added clinical value or the proposed alternative was not appropriate. A score of 9 indicated that 
checking for this item in the community pharmacy has a high added clinical value or that the proposed 
alternative is highly appropriate. 
After summarizing all panellists’ individual ratings a preliminary list of clinically relevant items for the tool was 
created, consisting of all items with a median score in the 7-9 range and all items rated “with disagreement”. 
To define “disagreement” we used the previously developed “D9R” definition: “considering all ratings, at least 
one falls in the lowest 3-point region and at least one falls in the highest”. We controlled results with the IPRAS 
method described in the RAND/UCLA user manual, however no discrepancies were detected(29).  
The panellists were also offered the possibility to add items and to suggest alternative treatments, which, to 
their judgement, would form a positive contribution to the screening tool. A summary of these items was made 
and the evidence supporting the suggested items was collected. These suggestions were also added to the 
preliminary list. Panellists were provided with the complete preliminary list of clinically relevant items for the 
tool two weeks prior to the second Delphi round. Only items scored with disagreement and suggested items or 
alternative treatments were to be discussed in the second Delphi round. 
Second Delphi round: face-to-face meeting 
During the second Delphi round in May 2013, all participating panellists were provided with their individual 
ratings and the ratings of the other group members. One general practitioner, one clinical pharmacist and one 
emergency physician could not attend, resulting in an 8-member panel. The moderator specifically focused the 
discussion on newly suggested items and on items for which there was “disagreement” among the panellists, 
as described in the RAND/UCLA manual(29). After discussing each part of the preliminary list of clinically 
relevant items for the GheOP³S-tool, panellists were asked to re-rate the items. No attempt was made to force 
panellists to consensus.  
The same summarizing method was used as in the first Delphi round, with the exception that all items rated 
“with disagreement” at this stage were deleted from the list. This resulted in a final list of clinically relevant 
items for the tool, which was sent out to all panellists for final approval. 
Retaining items applicable in contemporary community pharmacy practice 
Finally, the research team invited a panel of 7 Belgian community pharmacists to select those items that were 
applicable in the contemporary community pharmacy practice, using the same methodology as in steps 3 and 
4: a two-round Delphi consisting of a first written round and a second verbal round. Panellists were asked the 
following question “How do you rate the feasibility of a check on this item in the current community pharmacy 
practice?” and “How do you rate the feasibility of the proposed alternative strategy?”. To clarify that the goal 
of this developmental stadium was merely a selection of items that are presently applicable, pharmacists were 
instructed to consider practical aspects of pharmacy workflow and cost implications rather than assess the 
clinical relevance of each item.  
 RESULTS 
Literature review  
Eighteen published lists of potentially inappropriate medications for older patients were retrieved from the 
literature, mentioning a total of 398 different items, each of them categorized in one of the predefined parts of 
the GheOP³S-tool. After applying selection criteria mentioned in Appendix 1 (e.g., availability in at least 4 
European countries), a total of 121 items were retained, each complemented with the best available scientific 
evidence considering older patients. The specific lists used for each part of the GheOP³S-tool are displayed in 
Table 3. The flow of the items through the development process is shown in Table 4. 
First Delphi round: written individual evaluation 
In the first Delphi round, panellists reached immediate consensus on 73 of the 121 literature-based items (Part 
1: 33/53; Part 2: 21/33; Part 3: 5/7; Part 4: 12/24 and Part 5: 2/4), leaving 48 items for discussion in the second 
Delphi round. Furthermore, an additional 28 items were proposed by the panellists. Only one item concerning 
loperamide was considered of no clinical relevance and was omitted from the preliminary list of items for the 
tool. 53 of the 121 alternative therapeutic options were rated with disagreement and were also to be discussed 
in the second Delphi round.  
Second Delphi round: face-to-face meeting 
During the second Delphi round, all items rated “with disagreement” after the first round (48 items) were 
discussed as well as the 28 additional panellist-proposed items. The panel decided to group some of the items 
together (e.g. instead of including all individually named long-acting sulfonylurea derivatives such as 
glibenclamide and glimepiride, a new item was created: “Any long-acting sulfonylurea derivative”) (Table 1 Part 
1a). After discussion, consensus was reached for all proposed alternatives. After sending out the final list of 99 
clinically relevant items and their therapeutic alternatives for approval, no further changes were requested by 
participating panellists.  
Retaining items applicable in contemporary community pharmacy practice 
The panel of community pharmacists selected 83 items that they found to be applicable in the contemporary 
community pharmacy setting. One DDI was divided into two different items because of feasibility of the 
management plan (oral antidiabetic/insulin + beta blocker replaced by: oral antidiabetic/insulin + non-selective 
beta-blocker and oral antidiabetic/insulin + cardioselective beta-blocker). The 83 items define the final 
GheOP³S-tool (Table 1 and Table 2). For all of these items, extended information with rationales, management 
plans and scientific literature was compiled (currently only available in Dutch and French(34)). Items with 
clinical relevance for primary care, but not (yet) applicable in the community pharmacy practice, are displayed 
in Table 5. 
 DISCUSSION 
Main finding of this study 
In this study, we developed the GheOP³S-tool, a screening tool consisting of 83 items for identifying PIP in older 
patients in the community pharmacy practice. The items of the GheOP³S-tool were categorized in 5 different 
parts: Part 1: Potentially inappropriate drugs, independent of diagnosis, Part 2: Potentially inappropriate drugs, 
dependent on diagnosis, Part 3: PPOs, Part 4: DDIs of specific relevance and Part 5: General care-related items 
to be addressed in the community pharmacy (Table 1 and Table 2). For every item, an alternative therapeutic 
option was offered.  
What is already known on this topic 
Worldwide, the need for PIP-screening is rising in order to reduce prevalence of ADE(35, 36). As PIP-screening 
is part of pharmaceutical care, it is an assigned task of the community pharmacist(37, 38). Therefore, it is 
surprising that screening tools, specifically developed for this setting, are lacking. Community pharmacists have 
nevertheless shown to be effective in detecting PIP, even when non-specific or adapted tools were used(9, 25, 
39). The access to both the over the counter (OTC) and prescription medication record is also a major benefit, 
as missing OTC-data is an established risk factor for overlooking PIP in older patients(40). Moreover, including a 
pharmacist in a multidisciplinary team to approach a patient’s pharmacotherapy has been shown to be the 
safest and most rational way of prescribing(9).  
What this study adds 
An ideal screening tool for routine use in community pharmacy practice should be user-friendly, evidence-
based, inexpensive to apply and interchangeable between countries. To meet these requirements, the 
GheOP³S-tool was developed as an explicit screening tool designed for community pharmacists. Where 
practical issues with implicit lists may arise (i.e. often lacking the necessary clinical and laboratory information), 
an explicit screening tool provides community pharmacists with a reference that supports pragmatic PIP-
screening in a systematic and straightforward way. Moreover, the explicit character of the GheOP³S-tool allows 
future automatisation of the screening, giving pharmacists the time to focus on checking patient-specific 
relevance, on inter-care giver communication and on drawing up a management plan. Furthermore, the 
grouping of items in Part 1a (e.g., “any non-steroidal anti-inflammatory drug (NSAID)” instead of naming each 
locally marketed NSAID) facilitates transition between countries, where different drugs in a particular drug 
class are available. Additionally, it anticipates the commercialisation of new molecules that were not yet 
marketed at the time of the tool-development.  
A unique aspect of the GheOP³S-tool is the incorporation of a subset of items that evaluates the delivery of 
pharmaceutical care to the community-dwelling older patient (Table 1, Part 5: “General care-related items to 
be addressed in the community pharmacy”). In this section, the community pharmacist checks in an implicit 
way whether sufficient basic pharmaceutical care is provided. This includes – for example – verifying the need 
for a medication scheme or a regular evaluation of the medication adherence.  
Limitations of this study 
The development of the presented GheOP³S-tool using the RAND/UCLA methodology has some limitations. 
However, the methodological quality of the development was guaranteed by a thorough selection of the 
participating experts, extended scientific evidence for all included items and information about prevalence of 
ADEs attributable to PIP. Moreover, the setting in which the tool should be used was sufficiently taken into 
account by adding an extra step in the development process and by providing panellists with access to 
prescribing and sales data of the proposed items. Because the GheOP³S-tool is designed for routine 
implementation, it is evident that also a feasibility study, which in the meantime has been initiated, is 
necessary. Additionally, as well as for all explicit screening tools, it is stressed that the screening is aimed at 
assisting in clinical decision making for the older patients and not at making the decision on its own. We 
emphasize that an eventual adaptation of the treatment plan remains the result of a shared decision-making 
process. Finally, although all currently employed pharmacists have an adequate education in pharmacology, 
basic pathophysiology, basic diagnostic testing and pharmacotherapy, PIP-screening, on the other hand, was 
barely a part of the curriculum. The delivery of continuing post-academic professional development will 
therefore be a prerequisite for the correct implementation of the GheOP³S-tool and correct interpretation of 
results.  
Implications for future research 
Since the GheOP³S-tool is specifically developed for use in the community pharmacy, it could address 
previously described and widely spread PIPs in community-dwelling older patients, such as long-term proton 
pump inhibitors (PPI) or benzodiazepine use(41-43). As previous trials have shown that screening for PIP could 
have a positive clinical and economic impact(44, 45), a routine use of the GheOP³S-tool in the community 
pharmacy practice could have an impact on patient’s health and health care budgets. A future (cost-) 
effectiveness trial should therefore study the efficacy of a screening with the GheOP³S-tool by a community 
pharmacist on patient centred outcomes (i.e. hospital admissions, utilisation of health care resources, etc.). 
This way, the clinical and content validity of the screening tool as well as the efficacy of screening would be 
evaluated. Since polypharmacy and older age are major risk factors for PIPs and ADEs(24, 46), it is desirable to 
focus such a trial on an older population taking five or more drugs a day. However, if (limited) laboratory data 
such as renal function, would be available in trial context or in the community pharmacy because of policy 
changes, items from Table 5 can be added to the GheOP³S-tool.  
 CONCLUSION 
The GheOP³S-tool is the first explicit screening tool, specifically designed for use in the community pharmacy 
practice. The developmental design of the GheOP³S-tool offers a high flexibility in terms of adding or modifying 
specific parts of the tool. The GheOP³S-tool is intended to be used for PIP-screening in routine community 
pharmacy practice and to facilitate patient and caregiver communication. Using this tool, community 
pharmacists could play a supportive role as an advocate for the patient in which the most beneficial and 
clinically effective medication with the lowest possible risk for ADEs is delivered. Future research is required to 
determine whether screening for PIP with this tool results in detection of clinically relevant drug related 
problems and in optimization of drug therapy for older patients and whether it can reduce the cost of PIP.  
 Appendix 1: 
Criteria to withhold items in Part 1 (Potentially inappropriate medication for older patients, independent of 
diagnosis)  
Starting from all existing lists with explicit criteria on potentially inappropriate medication for older 
patients, independent of diagnosis, we withheld all items that were mentioned on at least 4 lists, as well as all 
OTC-available drugs mentioned on at least 1 list. Subsequently, we retained only those items considering drugs 
that are available in at least 4 European countries.  
Criteria to withhold items in Part 2 (Potentially inappropriate medication for older patients, dependent on 
diagnosis)  
Starting from all existing lists with explicit criteria on potentially inappropriate medication for older 
patients with certain diseases, we withheld all items mentioned on ≥2 lists. Items considering drugs not 
available in at least 4 European countries were deleted. Because of clinical relevance, 10 recommendations of 
the Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP)(32) and the HARM-Wrestling 
report(31) concerning drugs administered in patients with renal impairment were added to the list. 
Criteria to withhold items in Part 3 (Potential Prescribing Omissions)  
Starting from all existing lists with explicit criteria on potential prescribing omissions in older patients, 
we only withheld items confirmed by recommendations of the HARM-Wrestling report
(31)
 or ACOVE quality 
indicators
(30)
. Items considering drugs not available in at least 4 European countries were deleted. 
Criteria to withhold items in Part 4 (Drug-Drug interactions of specific relevance in older patients)  
Starting from all existing lists with explicit criteria on drug-drug interactions (DDI) of specific relevance 
in older patients, we only withheld  DDIs of which clinical relevance in older patients was confirmed through 
the HARM-Wrestling report
(31)
 or the systematic review of Hines et al
(33)
. DDIs considering drugs not available in 
at least 4 European countries were deleted.  
Criteria to withhold items in Part 5 (General care-related items for older patients to be addressed in the 
community pharmacy)  
Starting from all existing lists with explicit criteria on General care-related items for older patients to 
be addressed in the pharmacy, we withheld items if they have a contribution to drug-related problems (e.g. 
recording of fall frequency and long-term benzodiazepine use). None of the lists mentioned care-centred items. 
However, ACOVE-criteria
(30)
 and the HARM-Wrestling report
(31)
 mentioned four care-related items. For each of 
these statements, scientific evidence for being on the list was evaluated. 
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 Tables 
Table 1: The GheOP³S-tool 
Table 2: Drugs with high risk for anticholinergic (side-)effects (Adapted from Duran et al. (47)) 
Table 3: Published lists, used as basis for the GheOP³S-tool. 
Table 4: Flow of the items through the development process of the GheOP³S-tool. 
Table 5: Items deleted from each GheOP³S-part because of current inapplicability in the community pharmacy 
Table 1: The GheOP³S-tool 
Part 1a: Potentially inappropriate drugs, independent of diagnosis - Drug classes 
No. Item Alternative 
1 Any antidepressant ≥1year Check if indication is still present, if not: discontinue therapy 
If therapy is continued: check co-medication 
2 Any antipsychotic drug ≥1 month 1
st
 Consider need for chronic use (≈ Is original indication still present?) , if not: discontinue therapy 
2nd Always consider non-pharmacological approach 
3 Any drug for arterial vascular disorders  Therapeutic abstention  
Recommend non-pharmacological approach (compression hosiery, discuss referral to surgery with GP, physiotherapy...).  
4 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
- For sleeping disorders:  
Startup:  1
st
 Consider non-pharmacological approach 
 2nd Prefer intermediate acting benzodiazepine or Z-product at 1/2 dose of young adults  
>30 subsequent days: Consider non-pharmacological approach (sleep hygiene), provide GP with withdrawal plan and assure GP of support by pharmacists in 
withdrawal  
- For anxiety: consider non-pharmacological approach and switching to SSRI 
5 Any short  or long-acting benzodiazepine  
 
- Startup:  1
st
 Consider non-pharmacological approach 
 2
nd
 Prefer intermediate acting benzodiazepine or Z-product at 1/2 dose of young adults <30 subsequent days 
- Chronic: Consider non-pharmacological approach (sleep hygiene), provide GP with withdrawal plan and assure GP of support by pharmacists in withdrawal 
6 Any long-acting sulfonylurea derivative  Metformin or any short-acting sulfonylurea derivative  
7 Any nasal vasoconstrictor ≥1 month Hypertonic saline solution or referral to GP 
8 Any oral NSAID Consider need for anti-inflammatory therapy. If possible: paracetamol or stronger non-NSAID (eg. opioid) is safer choice  
If therapy is considered necessary, prefer low dose ibuprofen. 
 Avoid NSAIDs with high GI-risk (piroxicam, ketorolac) 
 Prefer ibuprofen/naproxen when CV-risk 
 Prefer NSAIDs with short half-life (ibuprofen, diclofenac) 
Always add gastroprotection (most evidence for PPI in standard dose) 
Closely monitor renal function or blood pressure depending on present diagnoses  
9 Any PPI at full dose
a
 ≥8 weeks  Consider need for chronic use and reduce dose if possible 
10 Any recently marketed drug (black triangles) Consider using drug with similar indication and more evidence in older patients 
11 Any sedating antihistaminic drug  1st Verify indication, if not valid: stop therapy or switch to appropriate therapy 
2nd If indication is valid: switch to non-sedating antihistaminic drug  
Part 1b: Potentially inappropriate drugs, independent of diagnosis - Specific molecules 
12 Alizapride Non pharmacological approach, if not sufficient: Reduce dose to 3 x 25 mg/day 
13 Bisacodyl Macrogol/lactulose 
14 Clonidine Consider other safer antihypertensive 
15 Codeine and its derivatives for acute cough Therapeutic abstention or safer alternative (eg., honey) 
16 Dabigatran Warfarin/Acetylsalicylic acid/Heparin, depending on indication 
17 Digoxin >0,125mg/day Digoxin ≤0,125mg/day or serum level between 0,5 and 0,8 µg/L 
18 Dipyridamole monotherapy (without ASA) Acetylsalicylic acid in low dose 
19 Ginkgo biloba or Panax ginseng Referral depending on underlying condition.  
20 Liquid paraffin Macrogol/lactulose 
21 Methyldopa  Consider other safer antihypertensive 
22 Metoclopramide Non pharmacological approach, if not sufficient: Reduce dose to 3 X 5 mg/day  
23 Pentazocine Consider paracetamol/codeine combination or pure morphinomimetic agent, depending on indication 
24 Phenobarbital Verify that GP checked diagnosis with prescribing neurologist 
25 Pseudoephedrine oral Short-term intranasal therapy (nasal vasoconstrictor <7 days or hypertonic saline solution)  
26 Rivaroxaban or Apixaban Warfarin/Acetylsalicylic acid/Heparin, depending on indication 
27 Senna glycosides Macrogol/lactulose 
28 Picosulfate Macrogol/lactulose 
29 Theophylline Reconsider indication, preferably stop theophylline 
30 Ticlopidine, new prescription Verify indication, prefer safer alternative 
31 Tramadol, new prescription Check if step-up approach was used. Paracetamol/Codeine could be more appropriate 
Part 2a: Potentially inappropriate drugs, dependent on diagnosis - Drug classes 
32 Any  antipsychotic other than quetiapine and clozapine with Parkinson’s disease Quetiapine and clozapine are preferred: they appear to be less likely to precipitate worsening of Parkinson’s disease 
33 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, 
Antispasmodics…) (cfr Table 2) with dementia or cognitive impairment 
Consider drug for same indication with less or none anticholinergic activity (cfr Table 2) 
34 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, 
Antispasmodics…) (cfr Table 2) with constipation 
Consider drug for same indication with less or none anticholinergic activity (cfr Table 2) 
If therapy is necessary: add osmotic laxative and apply non-pharmacological measures 
35 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, 
Antispasmodics…) (cfr Table 2) with BPH 
Consider drug for same indication with less or none anticholinergic activity (cfr Table 2) 
If therapy is necessary: check urinary residue shortly after start with anticholinergic drug. Recheck when suspicion of urine retention.  
36 Calcium Channel Blockers with constipation Prefer class of antihypertensive agent that hasn’t constipation as side-effect 
If calcium channel blocker is necessary, prefer dihydropyridines (amlodipine) and/or add osmotic laxative  
37 Non-selective beta-blockers with asthma or COPD Consider cardioselective beta-blocker or other class of antihypertensive drugs  
38 Oral corticosteroids >1 week with diabetes Closely monitor glycemic control and blood pressure  
Shorten therapy duration as much as possible  
Always warn patient about possible dysregulation 
39 Oral corticosteroids >1 week with hypertension Closely monitor  blood pressure and glycemic control 
Shorten therapy duration as much as possible  
Always warn patient about possible dysregulation 
40 Thiazide and loop diuretics with gout Prefer other class of antihypertensive drugs 
If diuretic is necessary; prefer potassium sparing (pay attention to renal impairment and probable interactions) 
Part 2b: Potentially inappropriate drugs, dependent on diagnosis - Specific molecules 
41 Alizapride with Parkinson’s disease 1st Always apply non-drug and diet therapy.  
2
nd
 If anti-emetic therapy is necessary, prefer domperidone in low dose only if no cardiac risk factors are present and no other QT-prolonging drugs are used 
42 Metoclopramide with Parkinson’s disease 1
st
 Always apply non-drug and diet therapy.  
2
nd
 If anti-emetic therapy is necessary, prefer domperidone in low dose only if no cardiac risk factors are present and no other QT-prolonging drugs are used 
 
Part 3: Potential prescribing omissions  
43 The patient is taking ≥ an equivalent of 7.5 mg of oral prednisone for ≥3 months and is not prescribed Ca/VitD supplementation and bisphosphonates. 
44 The patient is taking narcotic analgesics and is not prescribed appropriate preventative bowel regimen (preferably macrogol or lactulose). 
45 The patient has an elevated risk for osteoporosis (determined via FRAX-tool(48)) and is not prescribed Calcium/Vitamin D supplementation. 
46 The patient is taking oral corticosteroids for ≥1 month and is not prescribed Ca/VitD supplementation.  
47 The patient is not reminded and proposed to undergo yearly influenza vaccination. 
48 The patient is taking methotrexate and is not prescribed folic acid supplementation. 
 
Part 4: Drug-Drug interactions of specific relevance  
49 VKA + oral NSAIDs 1st Consider need for NSAID. If possible: paracetamol or stronger non-NSAID (eg. opioid)  is safer choice  
2
nd
 If NSAID is unavoidable, prefer low dose ibuprofen, but always add gastroprotection (most evidence for PPI in standard dose) and keep in mind to closely monitor renal 
function or blood pressure depending on present diagnoses 
50 RAAS-inhibitor + potassium sparing diuretic/potassium supplements/potassium 
containing drugsb 
1st Preferably change to non-potassium sparing diuretic/switch to non-potassium containing drug equivalent  
2nd If combination is unavoidable: monitor renal function and serum potassium and always inform patient about symptoms of hyperkalaemia  
51 VKA + Antiplatelet drugs (esp. ASA), unless prescribed by internist/cardiologist 1st Check if combination is appropriate (artificial valve, up to 3 months after acute coronary syndrome and for rheumatic mitral valve stenosis) 
2nd When combination is not appropriate: stop ASA and monitor INR 
52 VKA + TMP/SMX 1st Preferably switch to other antibiotic based on indication 
2nd If combination is unavoidable: monitor INR 
53 Oral NSAID + Oral Corticosteroids 1st Consider need for NSAID. If possible: paracetamol or stronger non-NSAID (eg. opioid) is safer choice  
2nd If NSAID is unavoidable, prefer low dose ibuprofen, but always add gastroprotection (most evidence for PPI in standard dose) and keep in mind to closely monitor renal 
function or blood pressure depending on present diagnoses 
54 Oral NSAID + Diuretic 1st Consider need for NSAID. If possible: paracetamol or stronger non-NSAID (eg. opioid)  is safer choice  
2nd If NSAID is unavoidable: monitor renal function, blood pressure and serum potassium 
55 Digoxin + Macrolide antibiotics 1
st
 Preferably switch to other antibiotic based on indication 
2nd If combination is unavoidable: monitor serum digoxin levels and always inform patient about signs of digoxin toxicity  
56 Digoxin + Verapamil/Diltiazem 1st Starting digoxin: use lowest possible dose  
2nd Starting diltiazem: check serum digoxin levels for 1 to 2 weeks  
3rd Starting verapamil: lower digoxin dose to 50-70% of usual dose + check serum digoxin levels for 1 to 2 weeks  
4th Altering dose of verapamil/diltiazem: alter digoxin dose using serum digoxin levels 
Always inform patient about signs of digoxin toxicity 
57 Lithium + RAAS-inhibitors 1st Consider need for RAAS-inhibitor  
2nd If combination is unavoidable: monitor lithium levels within 3-5 days after starting RAAS-inhibitor and always inform patient about signs of lithium toxicity 
58 Lithium + Oral NSAID 1st Consider need for NSAID. If possible: paracetamol or stronger non-NSAID (eg. opioid)  is safer choice 
2nd If combination is unavoidable: determine lithium levels before starting NSAID, give NSAID with strict schedule, check lithium levels after 3 days and modify intake dosage. Act 
similarly when NSAID is stopped and always inform patient about signs of lithium toxicity 
59 Lithium + Diuretics 1st Consider need for diuretic. If possible: replace with appropriate alternative. 
2nd If combination is unavoidable: determine lithium levels before starting diuretic, avoid 'on demand' use of diuretic, determine lithium levels after 3 days and modify intake 
dosage. Act similarly when diuretic is stopped and always inform patient about signs of lithium toxicity 
60 Theophylline + Quinolones/Macrolides 1st Consider switching to other antibiotic based on indication 
2nd If combination is unavoidable: monitor theophylline levels and always consider stopping theophylline  
61 RAAS-inhibitor + Oral NSAID 1st Consider need for NSAID. If possible: paracetamol or stronger non-NSAID (eg. opioid)  is safer choice.  
2nd If NSAID is unavoidable: monitor renal function, blood pressure and serum potassium 
62 Oral NSAID + SSRI/SNRI 1st Consider need for NSAID. If possible: paracetamol or stronger non-NSAID (eg. opioid) is safer choice  
2nd If NSAID is unavoidable, prefer low dose ibuprofen, but always add gastroprotection (most evidence for PPI in standard dose) and keep in mind to closely monitor renal 
function or blood pressure depending on present diagnoses 
63 RAAS-inhibitor + TMP/SMX 1
st
 Preferably switch to other antibiotic based on indication 
2nd If combination is unavoidable: monitor renal function and potassium level 
64 Oral antidiabetics/insulin + non-selective beta-blocker 1st Always change to cardioselective beta-blocker (also relevant for eye drops)  
2nd Inform patient about possible changes in awareness of hypoglycaemia  
65 Oral antidiabetics/insulin + cardioselective beta-blocker 1st Consider need for beta-blocker + check glycemic control  
2nd Inform patient about possible changes in awareness of hypoglycaemia  
66 Alprazolam/Midazolam/Triazolam/Zolpidem/Zopiclone + Strong CYP3A4 inhibitor 1st Preferably stop benzodiazepine use during treatment with CYP3A4 inhibitor  
2nd Switch to equivalent drug with less or without CYP3A4 inhibiting activity 
67 CCB + Strong CYP3A4 inhibitor Preferably switch to equivalent drug with less or without CYP3A4 inhibiting activity 
68 Oral NSAID + Antipletelet drugs 1st Consider need for NSAID. If possible: paracetamol or stronger non-NSAID (eg. opioid) is safer choice  
2
nd
 If NSAID is unavoidable, prefer low dose ibuprofen, but always add gastroprotection (most evidence for PPI in standard dose) and keep in mind to closely monitor renal 
function or blood pressure depending on present diagnoses 
69 Phenytoin + TMP/SMX 1st Preferably switch to other antibiotic based on indication 
2
nd
 If combination is unavoidable: monitor phenytoin levels 
70 First dose RAAS-inhibitor at full dosage + pre-treatment with diuretic 1
st
 Start RAAS-inhibitor in lowest possible dose for 3 days  
2nd Always give RAAS-inhibitor first 3 days at night and diuretic in the morning 
3
rd
  Always inform patient about possible orthostatic effect 
71 Tamoxifen + strong CYP2D6 inhibitors  Prefer equivalent drug with less or without CYP2D6 inhibiting activity  
72 Calcium + Quinolones/Tetracyclines 1
st
 Use Calcium minimum 2 hours after quinolone/tetracycline or take quinolone/tetracycline 6 hours after intake of Calcium 
2nd If not possible: Stop calcium  
73 Calcium + Stontium ranelate 1st Use Calcium minimum 2 hours after strontium ranelate or take strontium ranelate 6 hours after intake of Calcium  
2
nd
 If not possible: Stop calcium  
74 Calcium + Levothyroxine 1
st
 Use Calcium
 
minimum 2 hours after levothyroxine drug or take levothyroxine 6 hours after intake of 
 
Calcium  
2
nd
 If not possible: Stop calcium  
75 Bisphosphonate + Calcium, Magnesium, Zinc, Iron or Aluminium 1
st
 Use complexing agent minimum 2 hours after bisphosphonate  
2
nd
 If not possible: Switch to equivalent drug without complexing activity 
76 VKA + Vitamin K containing drugs/supplements
c
 1
st
 Switch to equivalent drug/supplement without Vitamin K 
2
nd
 If not possible: Monitor INR 
77 Any combination of anticholinergic drug 1
st 
Replace 1 of the drugs by an equivalent with less or without anticholinergic activity 
2nd  Always advise patients to report anticholinergic side-effects 
 
Part 5: General care-related items to be addressed in the community pharmacy 
78 Dispensation of over-the-counter medication (NSAID, ASA…) was not added in the electronic patient record.  
79 Contra-indications that can unambiguously be derived from patient’s medication were not added to the electronic patient record.  
80 Availability of assistance in medication/health issues (by nurse, neighbour, children etc.) was not checked nor discussed in frail older patients or older patients with reduced cognition, especially when taking drugs needing strict intake scheme. 
81 The patient was not asked which aspects of pharmaceutical care could be improved for him/her (Translated into practical questions for the specific patient: e.g. correct inhaler use, splitting tablets…).  
82 Adherence for all chronic medication was not checked or discussed during the past year (refill rate). 
Adherence for all new medication was not checked or discussed at first refill during the past year? 
83 Polypharmacy patients (chronically taking ≥ 5 drugs) were not questioned about whether a clear medication scheme was available to him/her. 
 
ASA: Acetylsalicylic acid; BPH: Benign prostatic hyperplasia; CCB: Calcium Channel Blocker; COPD: Chronic Obstructive Pulmonary Disease; CV-risk: Cardiovascular risk; GI-risk: Gastro-intestinal risk; GP: General Practitioner; NSAID: Non Steroidal Anti-Inflammatory Drug; INR: 
International Normalized Ratio; PPI: Proton Pump Inhibitor; RAAS-inhibitor: Renin-Angiotensin-Aldosteron System Inhibitors; SNRI: Serotonin and Noradrenalin Reuptake Inhibitor; SSRI: Selective Serotonin Reuptake Inhibitor; TMP/SMX: Trimetoprim/Sulfamethoxazol; VKA: 
Vitamin K Antagonist. 
 
a Full dose defined as: >20 mg (es)omeprazole, >20mg pantoprazole, >30mg lansoprazole, >20mg rabeprazole  
b Some drugs contain considerable potassium amounts: Glucosamine in potassium salt (up to 300mg/tablet), oral nutritional supplements (up to 200mg/unit).... (Recommended Daily Dose: 3000mg/day for ≥60 year old patients) 
c Some supplements such as oral nutritional supplements contain considerable Vitamin K amounts (up to 13µg/unit). (Recommended Daily Dose: 50-70µg/day for ≥60 year old patients) 
Table 2: Drugs with high risk for anticholinergic (side-)effects (Adapted from Duran et al. (47)) 
High-potency anticholinergics Low-potency anticholinergics 
Acepromazine Hydroxyzine Alimemazine Fluoxetine Prochlorperazine 
Amitriptyline Hyoscyamine Amantadine Fluvoxamine Promazine 
Atropine Imipramine Baclofen Haloperidol Quetiapine 
Belladonna Alkaloids Levomepromazine Bromocriptine Hydrocodone Ranitidine 
Brompheniramine Meclozine Carbamazepine Ketorolac Risperidone 
Chlorphenamine Nortriptyline Cetirizine Lithium Temazepam 
Chlorpromazine Orphenadrine Chlordiazepoxide Loperamide Theophylline 
Clemastine Oxybutynin Cimetidine Loratadine Tramadol 
Clomipramine Procyclidine Citalopram Loxapine Trazodone 
Clozapine Promethazine Clonazepam Meperidine 
(=Pethidine) 
Triazolam 
Cyproheptadine Propantheline Codeine Methadone  
Darifenacin Pyrilamine Cyclobenzaprine Methocarbamol   
Dexchlorpheniramine Scopolamine Diazepam Mirtazapine  
Dicyclomine Thioridazine Digitoxin Morphine   
Dimenhydrinate Tizanidine Disopyramide Olanzapine  
Diphenhydramine Tolterodine Domperidone Oxcarbazepine  
Doxepin  Trihexyphenidyl Dosulepin Oxycodone  
Flavoxate Trimipramine Entacapone Paroxetine  
Fluphenazine Tropatepine Fentanyl Phenelzine  
Homatropine  Fexofenadine Pimozide  
Remark: Tiotropium and ipratropium not included because of low risk for systemic side-effects after inhalation.  
 
Table 3: Published lists, used as basis for the GheOP³S-tool. 
 Part 1 Part 2 Part 3 Part 4 Part 5 
Beers-list (2012 update) (10) X X  X  
Austrian list(12) X     
Australian list(11) X X    
Laroche-criteria(13) X   X  
Rancourt-criteria(14) X   X  
PRISCUS-list(15) X     
Lindblad-list(16)  X    
NORGEP-criteria(17) X   X  
McLeod-criteria(18) X X  X  
IPET(19) X X    
START(20)   X   
STOPP(21) X X  X  
Winit-Watjana-criteria(22) X X  X  
Zhan-criteria(23) X     
ACOVE-criteria(30)   X  X 
HARM-Wrestling report(31)  X X X X 
KNMP-guidelines(32)  X    
Hines et al(33)    X  
ACOVE: Assessing Care of Vulnerable Elders; HARM: Hospital Admissions Related to Medication; IPET: improving prescribing in the 
elderly tool; KNMP: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie NORGEP: Norwegian General Practice; START: 
screening tool to alert to right treatment; STOPP: screening tool of older people's prescriptions;  
  
Table 4: Flow of the items through the development process of the GheOP³S-tool.   
 Part 1 Part 2 Part 3 Part 4 Part 5 Total 
Number of different items retrieved in the literature  188 67 22 117 4 398 
Number of items in literature-based list of potential items  53 33 7 24 4 121 
Number of items added during the first Delphi round  13 1 3 5 6 28 
Number of items in preliminary list of clinically relevant items  65 34 10 29 10 148 
→ of which to be discussed in second Delphi round because of 
‘disagreement’ 
33 13 5 17 8 76 
Number of items in final list of clinically relevant items  32 26 7 28 6 99 
Number of items in the GheOP³S-tool  31 11 6 29 6 83 
 
 Table 5: Items deleted from each GheOP³S-part because of current inapplicability in the community pharmacy 
Part 1: Drugs, inappropriate for older patients, independent of diagnosis 
 Sotalol for rate control 
Part 2: Drugs, inappropriate for older patients, dependent on diagnosis 
RAAS-inhibitors in renal impairment 
Any potassium sparing diuretic in renal impairment 
Chlortalidon and thiazides in renal impairment 
Allopurinol in renal impairment 
Amoxicillin with full dose clavulanic acid in renal impairment 
Ciprofloxacin in renal impairment 
Dabigatran in renal impairment 
Digoxin in renal impairment 
Diltiazem in congestive heart failure 
Metformin in renal impairment 
Nitrofurantoin in renal impairment 
Norfloxacin in renal impairment 
Sotalol in renal impairment 
Verapamil in congestive heart failure 
Part 3: PPOs for older patients 
 When a patients has elevated total cholesterol, a statin in secondary prevention should be started 
 when the patient has a good life expectancy 
Part 4: Drug-Drug interactions of specific relevance in older patients 
 None 
Part 5: General care-related items for older patients to be addressed in the community pharmacy 
 None  
  
 REFERENCES 
1. Pammolli F, Riccaboni M, Magazzini L. The sustainability of European health care systems: beyond income and aging. Eur J 
Health Econ. 2012;13(5):623-34. 
2. Sikdar KC, Dowden J, Alaghehbandan R, MacDonald D, Wang PP, Gadag V. Adverse Drug Reactions in Elderly Hospitalized 
Patients: A 12-Year Population-Based Retrospective Cohort Study. Annals of Pharmacotherapy. 2012;46(7-8):960-71. 
3. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113-21. 
4. Passarelli MCG, Jacob W, Figueras A. Adverse drug reactions in an elderly hospitalised population - Inappropriate prescription is a 
leading cause. Drugs & Aging. 2005;22(9):767-77. 
5. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can 
it be measured and optimised? Lancet. 2007;370(9582):173-84. 
6. Fu AZ, Jiang JZ, Reeves JH, Fincham JE, Liu GG, Perri M. Potentially inappropriate medication use and healthcare expenditures in 
the US community-dwelling elderly. Med Care. 2007;45(5):472-6. 
7. Ryan C, O'Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary 
care. British Journal of Clinical Pharmacology. 2009;68(6):936-47. 
8. Opondo D, Eslami S, Visscher S, de Rooij SE, Verheij R, Korevaar JC, et al. Inappropriateness of Medication Prescriptions to Elderly 
Patients in the Primary Care Setting: A Systematic Review. PLoS One. 2012;7(8). 
9. Kaur S, Mitchell G, Vitetta L, Roberts MS. Interventions that can reduce inappropriate prescribing in the elderly: a systematic 
review. Drugs Aging. 2009;26(12):1013-28. 
10. Fick D, Semla T, Beizer J, Dombrowski R, Brandt N, DuBeau CE, et al. American Geriatrics Society Updated Beers Criteria for 
Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2012;60(4):616-31. 
11. Basger BJ, Chen TF, Moles RJ. Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA 
appropriateness method. BMJ open. 2012;2(5). 
12. Mann E, Bohmdorfer B, Fruhwald T, Roller-Wirnsberger RE, Dovjak P, Duckelmann-Hofer C, et al. Potentially inappropriate 
medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochen. 2012;124(5-6):160-9. 
13. Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin 
Pharmacol. 2007;63(8):725-31. 
14. Rancourt C, Moisan J, Baillargeon L, Verreault R, Laurin D, Gregoire JP. Potentially inappropriate prescriptions for older patients 
in long-term care. BMC geriatrics. 2004;4:9. 
15. Holt S, Schmiedl S, Thurmann PA. Potentially Inappropriate Medications in the Elderly: The PRISCUS List. Dtsch Arztebl Int. 
2010;107(31-32):543-U39. 
16. Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER, et al. Clinically important drug-disease interactions and their 
prevalence in older adults. Clin Ther. 2006;28(8):1133-43. 
17. Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB, Straand J. The Norwegian General Practice (NORGEP) criteria for assessing 
potentially inappropriate prescriptions to elderly patients. Scand J Prim Health Care. 2009;27(3):153-9. 
18. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: A national 
consensus panel. Can Med Assoc J. 1997;156(3):385-91. 
19. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. The 
Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. 2000;7(2):103-7. 
20. Barry PJ, Gallagher P, Ryan C, O'Mahony D. START (screening tool to alert doctors to the right treatment)an evidence-based 
screening tool to detect prescribing omissions in elderly patients. Age and Ageing. 2007;36(6):632-8. 
21. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START 
(Screening Tool to Alert Doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72-83. 
22. Winit-Watjana W, Sakulrat P, Kespichayawattana J. Criteria for high-risk medication use in Thai older patients. Arch Gerontol 
Geriatr. 2008;47(1):35-51. 
23. Zhan CL, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, et al. Potentially inappropriate medication use in the 
community-dwelling elderly - Findings from the 1996 Medical Expenditure Panel Survey. Jama-Journal of the American Medical Association. 
2001;286(22):2823-9. 
24. Lechevallier-Michel N, Gautier-Bertrand M, Alperovitch A, Berr C, Belmin J, Legrain S, et al. Frequency and risk factors of 
potentially inappropriate medication use in a community-dwelling elderly population: results from the 3C Study. Eur J Clin Pharmacol. 
2005;60(11):813-9. 
25. Ryan C, O'Mahony D, O'Donovan DO, O'Grady E, Weedle P, Kennedy J, et al. A comparison of the application of STOPP/START to 
patients' drug lists with and without clinical information. International journal of clinical pharmacy. 2013;35(2):230-5. 
26. Galvin R, Moriarty F, Cousins G, Cahir C, Motterlini N, Bradley M, et al. Prevalence of potentially inappropriate prescribing and 
prescribing omissions in older Irish adults: findings from The Irish LongituDinal Study on Ageing study (TILDA). European journal of clinical 
pharmacology. 2014;70(5):599-606. 
27. Maio V, Yuen EJ, Novielli K, Smith KD, Louis DZ. Potentially inappropriate medication prescribing for elderly outpatients in Emilia 
Romagna, Italy: a population-based cohort study. Drugs Aging. 2006;23(11):915-24. 
28. Fick DM, Mion LC, Beers MH, Waller JL. Health Outcomes Associated With Potentially Inappropriate Medication Use in Older 
Adults. Research in nursing & health. 2008;31(1):42-51. 
29. Fitch K, Bernstein SJ, Aguilar MS, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA Appropriateness Method User's Manual  
[cited 2014 April 14th]. Available from: http://www.rand.org/pubs/monograph_reports/MR1269.html. 
30. ACOVE quality indicators. Ann Intern Med. 2001;135(8):653-67. 
31. Ministry of Health WS. HARM-Wrestling report: a proposition from the expert group Medication Safety concerning specific 
intervention improving extramural medication safety on a short-term. 2009. 
32. KNMP. Labwaarden en Nierfunctie, uitwisseling van gegevens 2011. Available from: 
http://www.knmp.nl/downloads/samenwerken-kennis-delen/innovatieve-
apotheken/LabwaardenenNierfunctieuitwisselingvangegevens.pdf. 
33. Hines LE, Murphy JE. Potentially Harmful Drug-Drug Interactions in the Elderly: A Review. Am J Geriatr Pharmacother. 
2011;9(6):364-77. 
34. Pharmaceutical Care Unit. Ghent Older People’s Prescriptions community Pharmacy Screening tool: Rationales, management 
plans and additional information. 2014. Available from: 
http://www.ugent.be/fw/nl/onderzoek/bioanalyse/farmzorg/tools.htm/gheops.htm. 
35. Price SD, Holman CD, Sanfilippo FM, Emery JD. Association between potentially inappropriate medications from the Beers criteria 
and the risk of unplanned hospitalization in elderly patients. The Annals of pharmacotherapy. 2014;48(1):6-16. 
36. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ. Inappropriate prescribing predicts adverse drug events in older adults. 
The Annals of pharmacotherapy. 2010;44(6):957-63. 
37. World Health Organization. The role of the pharmacist in the health care system 1994 [cited 2014 June 3]. Available from: 
http://apps.who.int/medicinedocs/en/d/Jh2995e/. 
38. European Directorate for the Quality of Medicines & HealthCare. Pharmaceutical Care - Policies and Practices for a Safer, More 
Responsible and Cost-effective Health System: Dr S. Keitel; 2012 [cited 2014 June 3]. Available from: 
http://www.edqm.eu/en/pharmaceutical-care-1517.html. 
39. Kwint HF, Faber A, Gussekloo J, Bouvy ML. Completeness of medication reviews provided by community pharmacists. J Clin 
Pharm Ther. 2014;39(3):248-52. 
40. Olesen C, Harbig P, Barat I, Damsgaard EM. Absence of 'over-the-counter' medicinal products in on-line prescription records: a 
risk factor of overlooking interactions in the elderly. Pharmacoepidemiol Drug Saf. 2013;22(2):145-50. 
41. Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling 
older patients. Br J Clin Pharmacol. 2014;77(1):201-10. 
42. Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly--a modern epidemic? European journal of clinical 
pharmacology. 2012;68(7):1085-94. 
43. Barnett K, McCowan C, Evans JM, Gillespie ND, Davey PG, Fahey T. Prevalence and outcomes of use of potentially inappropriate 
medicines in older people: cohort study stratified by residence in nursing home or in the community. BMJ quality & safety. 2011;20(3):275-
81. 
44. Gallagher PF, O'Connor MN, O'Mahony D. Prevention of Potentially Inappropriate Prescribing for Elderly Patients: A Randomized 
Controlled Trial Using STOPP/START Criteria. Clin Pharmacol Ther. 2011;89(6):845-54. 
45. McMullin ST, Hennenfent JA, Ritchie DJ, Huey WY, Lonergan TP, Schaiff RA, et al. A prospective, randomized trial to assess the 
cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999;159(19):2306-9. 
46. Pitkala KH, Strandberg TE, Tilvis RS. Inappropriate drug prescribing in home-dwelling, elderly patients: a population-based 
survey. Arch Intern Med. 2002;162(15):1707-12. 
47. Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 
2013;69(7):1485-96. 
48. World Health Organization Collaborating Centre for Metabolic Bone Diseases. Fracture Risk Assessment Tool United Kingdom: 
University of Sheffield. Available from: https://www.shef.ac.uk/FRAX/tool.jsp. 
 
 
